Eight IPOs raised a combined $29.3 billion in July, joined by three direct listings. New listings raised more than six times July’s 10-year historical average ($4.7B), driven almost entirely by Korea-listed SK hynix (SKHY), which raised $26.5 billion in ...read more
One IPO priced this past week, joined by four SPACs. Cardiovascular disease biotech Scribe Therapeutics (SCTX) upsized and priced at the high end to raise $129 million at a $273 million market cap. Scribe is developing in vivo CRISPR-based therapies, with an ...read more
Scribe Therapeutics, a Phase 1 biotech developing CRISPR genetic therapies for high cholesterol, raised $129 million by offering 8.6 million shares at $15, the high end of the $13 to $15 range. The company offered 1.4 million more shares than anticipated....read more
Renaissance Capital’s July IPO Market Update
Eight IPOs raised a combined $29.3 billion in July, joined by three direct listings. New listings raised more than six times July’s 10-year historical average ($4.7B), driven almost entirely by Korea-listed SK hynix (SKHY), which raised $26.5 billion in ...read more
IPO Winners & Losers: Jersey Mike's, Bubble Baths, and Biotech Wins
Welcome back to Renaissance Capital’s IPO Winners and Losers, the weekly podcast breaking down the biggest stories shaping the IPO market. Click here to get the newsletter in your inbox every week.
...read moreUS IPO Weekly Recap: CRISPR biotech pops 44% as more names join the IPO pipeline
One IPO priced this past week, joined by four SPACs. Cardiovascular disease biotech Scribe Therapeutics (SCTX) upsized and priced at the high end to raise $129 million at a $273 million market cap. Scribe is developing in vivo CRISPR-based therapies, with an ...read more
Cardiovascular disease biotech Scribe Therapeutics prices upsized IPO at $15, the high end of the range
Scribe Therapeutics, a Phase 1 biotech developing CRISPR genetic therapies for high cholesterol, raised $129 million by offering 8.6 million shares at $15, the high end of the $13 to $15 range. The company offered 1.4 million more shares than anticipated....read more